Treatment of the mouse model of mucopolysaccharidosis type IIIB with lentiviral-NAGLU vector.
The Sanfilippo syndrome type B (mucopolysaccharidosis IIIB) is an autosomal recessive disorder due to mutations in the gene encoding NAGLU (alpha-N-acetylglucosaminidase), one of the enzymes required for the degradation of the GAG (glycosaminoglycan) heparan sulphate. No therapy exists for affected patients. We have shown previously the efficacy of lentiviral-NAGLU-mediated gene transfer in correcting in vitro the defect on fibroblasts of patients. In the present study, we tested the therapy in vivo on a knockout mouse model using intravenous injections. Mice (8-10 weeks old) were injected with one of the lentiviral doses through the tail vein and analysed 1 month after treatment. A single injection of lentiviral-NAGLU vector resulted in transgene expression in liver, spleen, lung and heart of treated mice, with the highest level reached in liver and spleen. Expression of 1% normal NAGLU activity in liver resulted in a 77% decrease in the GAG content; more remarkably, an expression of 0.16% normal activity in lung was capable of decreasing the GAG level by 29%. Long-term (6 months) follow up of the gene therapy revealed that the viral genome integration persisted in the target tissues, although the real-time PCR analysis showed a decrease in the vector DNA content with time. Interestingly, the decrease in GAG levels was maintained in liver, spleen, lung and heart of treated mice. These results show the promising potential and the limitations of lentiviral-NAGLU vector to deliver the human NAGLU gene in vivo.
Di Natale
Paola
P
Department of Biochemistry and Medical Biotechnologies, University of Naples Federico II, Via S. Pansini n. 5, 80131 Naples, Italy. dinatale@unina.it
Di Domenico
Carmela
C
Gargiulo
Nadia
N
Castaldo
Sigismondo
S
Gonzalez Y Reyero
Enrico
E
Mithbaokar
Pratibha
P
De Felice
Mario
M
Follenzi
Antonia
A
Naldini
Luigi
L
Villani
Guglielmo R D
GR
D000118:Acetylglucosaminidase / Q000235:genetics* / Q000378:metabolism; D000818:Animals; D003587:Cytomegalovirus; D004195:Disease Models, Animal; D015316:Genetic Therapy; D005822:Genetic Vectors; D016679:Genome, Viral; D006025:Glycosaminoglycans / Q000378:metabolism; D016086:Lentivirus; D051379:Mice; D008817:Mice, Mutant Strains; D009084:Mucopolysaccharidosis III / Q000201:enzymology / Q000235:genetics / Q000628:therapy*; D010641:Phenotype; D011401:Promoter Regions, Genetic; D013997:Time Factors; D014018:Tissue Distribution; D014161:Transduction, Genetic
D006025:Glycosaminoglycans; C033079:alpha-N-acetyl-D-glucosaminidase; D000118:Acetylglucosaminidase